Marina Boban

Dr. Marina Boban


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2023 in Neurology International
Verified
Journal Article
Open access
PDF file
EPEna Španić Popovački
Ena Španić Popovački
MLMirjana Babić Leko
Mirjana Babić Leko
LHLea Langer Horvat
Lea Langer Horvat
KBKlara Brgić
Klara Brgić
ŽVŽeljka Vogrinc
Željka Vogrinc
Goran ŠimićGoran Šimić
Goran Šimić
Background: Individuals with specific TREM2 gene variants that encode for a Triggering Receptor Expressed on Myeloid cells 2 have a higher prevalence of Alzheimer’s disease (AD). By interacting with amyloid and apolipoproteins, the TREM2 receptor regulates the number of myeloid cells, phagocytosis, and the inflammatory response. Higher TREM2 expression has been suggested to protect against AD. However, it is extremely difficult to comprehend TREM2 signaling in the context of AD. Previous results are variable and show distinct effects on diverse pathological changes in AD, differences between soluble and membrane isoform signaling, and inconsistency between animal models and humans. In addition, the relationship between TREM2 and inflammasome activation pathways is not yet entirely understood. Objective: This study aimed to determine the relationship between soluble TREM2 (sTREM2) levels in cerebrospinal fluid (CSF) and plasma samples and other indicators of AD pathology. Methods: Using the Enzyme-Linked Immunosorbent Assay (ELISA), we analyzed 98 samples of AD plasma, 35 samples of plasma from individuals with mild cognitive impairment (MCI), and 11 samples of plasma from healthy controls (HC), as well as 155 samples of AD CSF, 90 samples of MCI CSF, and 50 samples of HC CSF. Results: CSF sTREM2 levels were significantly correlated with neurofibrillary degeneration, cognitive decline, and inflammasome activity in AD patients. In contrast to plasma sTREM2, CSF sTREM2 levels in the AD group were higher than those in the MCI and HC groups. Moreover, concentrations of sTREM2 in CSF were substantially higher in the MCI group than in the HC group, indicating that CSF sTREM2 levels could be used not only to distinguish between HC and AD patients but also as a biomarker to detect earlier changes in the MCI stage. Conclusions: The results indicate CSF sTREM2 levels reliably predict neurofibrillary degeneration, cognitive decline, and inflammasome activation, and also have a high diagnostic potential for distinguishing diseased from healthy individuals. To add sTREM2 to the list of required AD biomarkers, future studies will need to include a larger number of patients and utilize a standardized methodology.

16 April 2022 in Acta Neurologica Belgica
Verified
Journal Article
Closed access
PDF file
JSJosip Stojic
Josip Stojic
MPMaja Petrosanec
Maja Petrosanec
MMMilan Milosevic
Milan Milosevic
MBMarina Boban
Marina Boban
1

2 August 2017 in Acta Neurologica Belgica
Verified
Journal Article
Closed access
PDF file
MBMarina Boban
Marina Boban
KGKoraljka Gjadrov-Kuveždić
Koraljka Gjadrov-Kuveždić
JJJasminka Jakić-Razumović
Jasminka Jakić-Razumović

13 October 2023 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
MBMarina Boban
Marina Boban
AGAnja Tea Golubić
Anja Tea Golubić

12 May 2025 in Cortex
Verified
Journal Article
Closed access
MBMarina Boban
Marina Boban
LKLuciana Koren
Luciana Koren
AKAndro Koren
Andro Koren
AMAntonela Bazina Martinovic
Antonela Bazina Martinovic

25 May 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
EPEna Španić Popovački
Ena Španić Popovački
MLMirjana Babić Leko
Mirjana Babić Leko
LHLea Langer Horvat
Lea Langer Horvat
KBKlara Brgić
Klara Brgić
ŽVŽeljka Vogrinc
Željka Vogrinc
Goran ŠimićGoran Šimić
Goran Šimić
People with specific TREM2 gene variants are more prone to develop Alzheimer's disease (AD). The TREM2 receptor regulates the number of myeloid cells, phagocytosis, and the inflammatory response via interacting with apolipoproteins and amyloid. Higher TREM2 expression has been found to protect against AD. When TREM2 activity increases, the activity of genes involved in the activation of microglia cells decreases. This can improve the efficiency of phagocytosis. When TREM2 is highly expressed and the inflammasome is activated, the results are not always congruent. Therefore, this study aimed to discover how sTREM2 levels in CSF and plasma samples relate to other indices of AD pathology. We examined 98 AD plasma samples, 35 plasma samples of subjects with mild cognitive impairment (MCI), 11 healthy controls (HC) plasma samples, as well as 155 AD CSF samples, 90 MCI CSF samples, and 50 HC CSF samples. CSF sTREM2 levels were higher in the AD group than in the MCI and HC groups, in contrast to plasma sTREM2. This shows that CSF sTREM2 levels could be used to distinguish between healthy and AD patients. CSF sTREM2 levels were significantly correlated with neurofibrillary changes, cognitive decline, and inflammasome activity in AD patients. While our findings are consistent with previous research, future studies will need to include more patients and employ standardized methodological approaches to add CSF sTREM2 to the list of biomarkers for AD.